The antiinfective medicine sales in Australia have shown significant fluctuations over the past decade. After a gradual increase from 2013 to 2015, there was a dramatic spike in 2016, hitting a peak. However, this was followed by a substantial decline from 2017 to 2021, reaching its lowest in 2021. Post-2021, the market began to recover, with a 53.11% increase in 2022 and a moderate 6.02% growth in 2023, standing at 1,670 Million AUD. Forecasts from 2024 to 2028 predict a steady increase in sales with an average annual growth rate of 1.6%.
Key trends to watch include:
- Innovative drug development and approval processes.
- Shifts in disease prevalence and treatment protocols.
- Impact of regulatory changes and healthcare funding policies.
As of 2024, stakeholders should monitor advancements in antiinfective treatments and potential impacts of emerging infectious diseases on market demand.
